Eosinophilic inflammation in COPD: Prevalence and clinical characteristics

European Respiratory Journal

Volumn 44, Issue 6, 2014, Pages 1697-1700

  Singh, Dave ^a   Kolsum, Umme ^a   Brightling, Chris E ^b   Locantore, Nicholas ^c   Agusti, Alvar ^c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CELL PROTEIN; CLUB CELL PROTEIN 16; CORTICOSTEROID; INTERLEUKIN 5; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ADULT; ASTHMA; BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; EMPHYSEMA; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC INFLAMMATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; SCORING SYSTEM; SPUTUM LEVEL; TREATMENT OUTCOME; AGED; COHORT ANALYSIS; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADULT; AGED; COHORT STUDIES; EOSINOPHILIA; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84916235780     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162414     Document Type: Letter

References (13)

1. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198.
2. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-1485.
3. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27: 964-971.
4. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-1517.
5. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
6. Papi A, Luppi F, Franco F, et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 245-251.
7. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
8. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
9. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008; 31: 869-873.
10. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12: 146.
11. Gietema HA, Müller NL, Fauerbach PV, et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol 2011; 18: 661-671.
12. Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115.
13. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 2012; 13: 305-312.